Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06855654 · ClinicalTrials.gov registry record · NA

Promoting Resilience in Women With Breast Cancer (PRISM -MBC)

A NA study of Breast Cancer and Metastatic Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Recruiting
Registry status
NA
Development phase
120
Enrollment target
2
Study locations

NCT06855654: Recruiting NA study of Breast Cancer and Metastatic Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

NCT06855654 is a NA study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 120 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06855654, a NA study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.

RECRUITING
Registry status
NA
Development phase
120 participants
Enrollment target
2
Study locations

Study Summary

This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) intervention, overall and stratified by race, and to evaluate the feasibility and acceptability of the PRISM intervention in the MBC population. Black women with MBC have shorter survival from the time of metastatic diagnosis to death, compared to White women with clinically similar disease, and may have more rapid declines in quality of life over time. Adverse social determinants of health may play a role in these outcome disparities, due to both social barriers in accessing care, and through direct stress-mediated biological effects on the host and tumor microenvironment. Interventions to reduce stress and optimize resilience during treatment of MBC may improve quality of life and even improve disease outcomes; however, feasibility of face-to-face intervention during intensive medical treatment is limited. Thus, this study aims to demonstrate the feasibility of a remotely delivered resilience intervention, PRISM, already proven effective in other cancer settings, for MBC patients, and to gather preliminary efficacy data for a future randomized trial.

Primary Outcome

Resilience Score Change will be assessed baseline to 3 months using Connor Davidson Resilience Score, overall and stratified by race (Black/non-Black).

Interventions

  • BEHAVIORAL Promoting Resilience in Women with Breast Cancer (PRISM)

Study Locations (2)

Alabama

  • The University of Alabama - Birmingham

North Carolina

  • University of North Carolina - Chapel Hill

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-01-01
Est. Completion 2027-12-01
Phase NA

What NCT06855654 shows while recruiting

NCT06855654 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).

The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Promoting Resilience in Women with Breast Cancer (PRISM) is the first listed.

NCT06855654 reports a single indexed study location in Alabama, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06855654 about?

NCT06855654 is a clinical study titled "Promoting Resilience in Women With Breast Cancer (PRISM -MBC)". This pilot interventional study evaluates the change from baseline to post-intervention in resilience and other patient-reported outcomes for individuals with a recent diagnosis of metastatic breast cancer (MBC) participating in the Promoting Resilience in Women with Breast Cancer (PRISM) interventi...

What is the current status of trial NCT06855654?

This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-01-01. Estimated completion is 2027-12-01.

What conditions does trial NCT06855654 study?

This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer.

What interventions are being tested in trial NCT06855654?

The interventions under investigation include: Promoting Resilience in Women with Breast Cancer (PRISM) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06855654?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06855654 being conducted?

This trial has 2 study locations across Alabama, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06855654's enrollment target sits among peer trials

120 510th of 1224 higher than 703 of 1,224 other Breast Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06855654, the US trial registry maintained by the National Library of Medicine. NCT06855654 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.